Temasek-Backed Biotech Firm Innovent Seeks To Raise Up To $500M In HK IPO

Chinese biotech Innovent Biologics, Inc., backed by Singapore’s Temasek Holdings, is seeking to raise US$400 million to US$500 million in an initial public (IPO) offering in Hong Kong.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

LEAVE A REPLY